Compare Smith & Nephew plc (SNN) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs DENTSPLY SIRONA Inc — how do they compare? Smith & Nephew plc trades at $30.45 (market cap $12.64B), while DENTSPLY SIRONA Inc trades at $13.56 (market cap $2.70B). The key difference: Smith & Nephew plc is far larger — about 4.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| SNN | XRAY | |
|---|---|---|
Market Cap | $12.64B | $2.70B |
Sector | Health | Health |
52-Week High | $38.70 | $16.85 |
52-Week Low | $28.73 | $9.64 |
Enterprise Value | $15.41B | $4.84B |
Dividend Yield | 2.57% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Dentsply Sirona (XRAY) trades at $13.65, down 2.91% on the day, with a mixed technical picture showing a bullish moving average signal but overbought RSI levels. Fundamentally, the company reported a net loss of $598 million for 2025, with negative profit margins and an elevated EV/EBITDA of 91.48, though revenue remains stable near $3.7 billion. Recent news includes the appointment of a new CFO and expanded U.S. distribution partnerships, while the upcoming Q2 2026 earnings call on August 6 is a key near-term catalyst.
The outlook remains challenging due to persistent losses and margin pressure, offset by strategic growth initiatives. Investment opportunities lie in the company's market leadership and digital dentistry expansion, but risks include high debt levels, competitive pressures, and the need for a successful turnaround. Analyst consensus is Hold with a price target of $13.33, indicating limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
